Ambalal Sarabhai Enterprises Ltd
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
- Market Cap ₹ 276 Cr.
- Current Price ₹ 36.0
- High / Low ₹ 77.7 / 34.1
- Stock P/E 27.5
- Book Value ₹ 18.3
- Dividend Yield 0.00 %
- ROCE 8.60 %
- ROE 7.23 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 8.10% over past five years.
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 6.86% over last 3 years.
- Debtor days have increased from 65.4 to 82.1 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
105 | 124 | 132 | 134 | 125 | 150 | 133 | 163 | 197 | 170 | 173 | 196 | |
112 | 129 | 145 | 137 | 137 | 144 | 136 | 165 | 171 | 162 | 167 | 188 | |
Operating Profit | -7 | -4 | -13 | -3 | -12 | 6 | -3 | -2 | 25 | 8 | 6 | 8 |
OPM % | -7% | -3% | -10% | -2% | -9% | 4% | -2% | -1% | 13% | 5% | 3% | 4% |
2 | 13 | 95 | -2 | 25 | 8 | 24 | 40 | 33 | 12 | 10 | 5 | |
Interest | 11 | 10 | 4 | 5 | 3 | 3 | 4 | 3 | 2 | 3 | 6 | 4 |
Depreciation | 3 | 5 | 17 | 4 | 2 | 2 | 3 | 2 | 2 | 3 | 4 | 4 |
Profit before tax | -20 | -6 | 62 | -14 | 8 | 8 | 15 | 33 | 54 | 15 | 7 | 5 |
Tax % | 3% | 13% | 22% | 34% | 84% | 48% | 6% | 10% | 13% | 25% | 15% | -2% |
-20 | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 11 | 6 | 5 | |
EPS in Rs | -2.64 | -0.87 | 6.28 | -2.38 | 0.17 | 0.55 | 1.83 | 3.83 | 6.16 | 1.49 | 0.74 | 0.64 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 8% |
3 Years: | 0% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -6% |
3 Years: | -34% |
TTM: | 77% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 18% |
3 Years: | 1% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 13% |
3 Years: | 7% |
Last Year: | 7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
Reserves | -79 | -86 | -38 | -51 | -50 | -46 | -32 | -3 | 43 | 54 | 60 | 63 |
42 | 46 | 47 | 42 | 43 | 40 | 31 | 28 | 27 | 45 | 46 | 51 | |
128 | 132 | 94 | 93 | 128 | 144 | 111 | 108 | 84 | 70 | 67 | 79 | |
Total Liabilities | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 250 | 270 |
94 | 91 | 72 | 72 | 59 | 58 | 57 | 57 | 58 | 85 | 88 | 87 | |
CWIP | 0 | 1 | 9 | 3 | 14 | 24 | 0 | 1 | 12 | 4 | 0 | 0 |
Investments | 1 | 1 | 8 | 5 | 5 | 9 | 18 | 27 | 33 | 32 | 30 | 32 |
71 | 76 | 92 | 80 | 119 | 123 | 110 | 125 | 128 | 125 | 133 | 151 | |
Total Assets | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 250 | 270 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | -8 | -75 | 5 | -7 | 19 | -7 | -2 | 11 | 6 | 5 | -18 | |
-1 | 10 | 80 | -3 | 18 | -9 | 17 | 10 | 5 | -17 | -1 | 13 | |
-8 | -1 | -3 | -6 | -2 | -6 | -14 | -6 | -19 | 9 | -3 | -2 | |
Net Cash Flow | 2 | 1 | 2 | -4 | 8 | 3 | -4 | 2 | -3 | -2 | 1 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 74 | 83 | 79 | 100 | 84 | 79 | 87 | 52 | 59 | 55 | 82 |
Inventory Days | 95 | 86 | 72 | 66 | 75 | 61 | 76 | 58 | 48 | 62 | 58 | 75 |
Days Payable | 178 | 139 | 135 | 138 | 207 | 191 | 184 | 184 | 151 | 131 | 133 | 158 |
Cash Conversion Cycle | 12 | 22 | 20 | 6 | -32 | -46 | -29 | -39 | -50 | -10 | -19 | -2 |
Working Capital Days | -219 | -204 | -47 | -89 | -98 | -120 | -74 | -37 | 18 | 30 | 41 | 53 |
ROCE % | -16% | -19% | -44% | -1% | -5% | 16% | 25% | 18% | 34% | 11% | 7% | 9% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Jun
-
Intimation Under Regulation 30 Of SEBI (LODR)
30 May - Audited FY25 financial results approved; auditors and directors appointed; AGM scheduled for July 17, 2025.
-
Results - Audited Financial Results For Quarter Year Ended 31.03.2025
30 May - Audited financial results FY25 approved; auditor and director appointments; AGM on July 17, 2025 announced.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 30.05.2025
30 May - Audited FY25 financials approved; AGM on July 17, 2025; auditors and directors reappointed.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual Secretarial Compliance Report confirming regulatory adherence for FY ended March 31, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad